Oracle Corp (NYSE:ORCL) has teamed up with several Canadian healthcare organizations on Wednesday, with Lumeo Regional Health Information System choosing Oracle Health’s Clinical AI Agent for a pilot project. The initiative aims to streamline clinical documentation and alleviate administrative burdens for physicians.

Oracle Health AI Aids Canadian Healthcare

The integration of Oracle Health’s AI technology is expected to automatically generate narrative-rich draft notes from clinical interactions, allowing physicians to focus more on patient care rather than administrative tasks. This pilot project builds on the previous unification of these organizations under a single Oracle Health Foundation electronic health record (EHR), which facilitates seamless information sharing across the region.

Oracle’s Bearish Stock Trend Analysis

Currently, Oracle stock is trading approximately 15.4% below its 20-day simple moving average (SMA) and 34.4% below its 100-day SMA, reflecting a bearish trend. Over the past 12 months, shares have decreased by 7.87% and are positioned closer to their 52-week lows than highs, indicating ongoing weakness in the stock.

The RSI is at 26.63, which is considered oversold territory, suggesting that the stock may be undervalued in the short term. Meanwhile, the MACD is below its signal line, indicating bearish pressure on the stock.

The combination of oversold RSI and bearish MACD suggests mixed momentum.

Key Resistance: $156.50

Key Support: $137.50
Oracle’s Upcoming Earnings: Analysts’ Eyes on Growth

Investors are looking ahead to the next earnings report on March 9.

EPS Estimate: $1.56 (Up from $1.47 YoY)

Revenue Estimate: $16.90 billion (Up from $14.13 billion YoY)

Valuation: P/E of 29.1x (Indicates premium valuation)

Analyst Consensus & Recent Actions:

The stock carries a Buy Rating with an average price target of $305.45. Recent analyst moves include:

Scotiabank: Sector Outperform (Lowers Target to $220.00) (Feb. 3)

Piper Sandler: Overweight (Lowers Target to $240.00) (Feb. 3)

Morgan Stanley: Equal-Weight (Lowers Target to $213.00) (Jan. 23)
Oracle’s Premarket Price Movement

ORCL Price Action: Oracle shares were down 0.43% at $154.00 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo: Sundry Photography / Shutterstock.com

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.